arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Atara Biotherapeutics, Inc.

ATRA
$8.11 ▼ -0.32 (-3.80%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
54 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
44
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Atara Biotherapeutics, Inc. demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $121.9M
Dividend Yield —
Revenue Growth -96.4% ↗
Op. Margin None
ROIC 12.8% ↗
FCF / Share $-0.22 →
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$630.00K
↓ -96.4% —
Net Income Profit after all expenses
$-4.14M
— 0.0% —
Operating Margin Operating profit as % of sales
-160.7%
↓ -55.2% 86th
FCF / Share Free cash flow per share
$-0.22
↓ -1.7% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
60
Returns ↑
11
Financial Health
82
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 54 quarters